Jasuja Ravi, LeBrasseur Nathan K
From the Research Program in Men's Health: Aging and Metabolism, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (RJ); and Department of Physical Medicine and Rehabilitation and Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, Minnesota (NKL).
Am J Phys Med Rehabil. 2014 Nov;93(11 Suppl 3):S88-96. doi: 10.1097/PHM.0000000000000118.
Skeletal muscle is a fundamental organ in the generation of force and movement, the regulation of whole-body metabolism, and the provision of resiliency. Indeed, physical medicine and rehabilitation is recognized for optimizing skeletal muscle health in the context of aging (sarcopenia) and disease (cachexia). Exercise is, and will remain, the cornerstone of therapies to improve skeletal muscle health. However, there are now a number of promising biologic and small molecule interventions currently under development to rejuvenate skeletal muscle, including myostatin inhibitors, selective androgen receptor modulators, and an activator of the fast skeletal muscle troponin complex. The opportunities for skeletal muscle-based regenerative therapies and a selection of emerging pharmacologic interventions are discussed in this review.
骨骼肌是产生力量和运动、调节全身代谢以及提供弹性的重要器官。事实上，物理医学与康复在优化衰老（肌肉减少症）和疾病（恶病质）背景下的骨骼肌健康方面已得到认可。运动过去是、将来也仍将是改善骨骼肌健康疗法的基石。然而，目前有一些有前景的生物和小分子干预措施正在研发中，以恢复骨骼肌活力，包括肌肉生长抑制素抑制剂、选择性雄激素受体调节剂以及快速骨骼肌肌钙蛋白复合物激活剂。本文综述了基于骨骼肌的再生疗法的机遇以及一些新兴的药物干预措施。
